Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Notebook: EMA Focuses On EU Drug Supply Amid Fears Of Second Wave

Executive Summary

In this latest update to coronavirus developments in the EU, the European Medicines Agency outlines plans to monitor demand for medicines in anticipation of a possible second wave of the COVID-19 pandemic later this year. It has also updated its adverse drug reaction literature monitoring service to cover potential coronavirus treatments, and backed the use of ACE-inhibitors and sartans during the pandemic.

You may also be interested in...



EU Clinical Trials Regulation To Apply From December 2021

Executive Summary: The European Medicines Agency’s management board has decided on December 2021 as the go-live date for the EU Clinical Trials Information System. It will also meet later this month to elect the EMA’s new executive director to succeed Guido Rasi. 

GCP Inspections 'Indispensable' During Pandemic

The European Medicines Agency says good clinical practice inspections are indispensable even in the midst of a pandemic. It has set out requirements and specificities of undertaking inspections remotely where feasible. 

Gilead Files For Remdesivir Approval In EU

The much-anticipated EU filing for Gilead’s COVID-19 treatment is being reviewed quickly by the European Medicines Agency.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132046

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel